Most Commodities End November with Gains

Source: Associated Press, Sandy Shore (11/30/10)

"Silver was the standout for the month with a 14.4% increase."

Commodities wrapped up a strong November by posting price gains, especially metals and energy products.

The star performers were silver, palladium and gasoline. Gold traded above $1,400/oz. for the first time, silver set a settlement high for the year and oil hit a two-year high.

Much of the movement came amid shifts in the global economy. Early optimism about improving economies in Asia and emerging countries has given way to more recent concerns about European debt problems and the impact of China's actions to slow its robust growth.

Silver was the standout for the month with a 14.4% increase. The metal benefited from its reputation as a safer place to park money during uncertain times and for its industrial use.

It was the safe-haven side that boosted silver Tuesday amid ongoing concerns about whether Europe's financial problems will spread to other countries such as Portugal, Spain and Italy.

The other issue boosting silver is still unresolved tensions between North Korea and South Korea, CPM Group senior commodity analyst Rohit Savant said.

Silver for March delivery added $1.019, or 3.7%, to settle at $28.212 an ounce. Earlier in the month, it hit a high for the year of $28.906 an ounce.

Investors also poured money into gold, sending it to $1,410.10/oz. on Nov. 9. It was a record in dollar terms but well below its inflation-adjusted peak in the early 1980s.

On Tuesday, gold for February delivery added $18.60 to settle at $1,386.10/oz.

In other metals trading, December palladium rose $7.95 to settle at $700.95 an ounce. That's up 8.6% for November. January platinum added $21.80 to settle at $1,666.40/oz. That's a decline of 2.6% since Nov. 1.

March copper rose to $3.8255/lb., which was 2.4% higher than it began the month.

Novavax Shares Shoot 65% Higher on Phase 3 COVID-19 Vaccine Trial's 89.3% Effectiveness
Source: Streetwise Reports (01/29/2021)

Novavax Inc. shares established a new 52-week high after the firm's COVID-19 vaccine demonstrated an 89.3% efficacy rate in a Phase 3 trial in the U.K. and also showed efficacy against the South African variant in a Phase 2b trial.

Abiomed Shares Gain 8% After Firm Announces Record Q3 Revenue of $232 Million
Source: Streetwise Reports (01/28/2021)

Shares of cardiac medical device maker Abiomed Inc. traded higher after the company reported record revenue for Q3/21 despite the impact from COVID-19.

Sorrento Shares Rise 35% After Firm Posts Positive Data from Phase 1b ICU COVID-19 Trial
Source: Streetwise Reports (01/27/2021)

Shares of Sorrento Therapeutics traded higher after the company released positive preliminary results from it of Phase 1b COVI-MSC™ Study for treatment of hospitalized ICU COVID-19 patients.

Junior Mining Sector 'the Best Value in the Space'
Source: Streetwise Reports (01/27/2021)

The StreetSmart Live! Broadcast on Jan. 26, 2021, focused on metals and why now is a good time for investors to be looking at them and the mining space. John Newell, independent analyst and portfolio manager, and John Feneck, mining sector expert and president of Feneck Consulting, addressed the status of the current metals market. CEOs of the three metals-focused companies comprising the Metallic Group of Companies—Group Ten Metals, Metallic Minerals and Granite Creek Copper—discussed their projects.

Vir Shares Climb 48% on Initial Phase 1 Chronic Hepatitis B Trial Data
Source: Streetwise Reports (01/26/2021)

Vir Biotechnology shares traded higher after the company reported data from its Phase 1 Chronic Hepatitis B Study that showed VIR-3434 significantly and rapidly reduced hepatitis B surface antigen.

Aurinia Pharma Shares Open at 52-Week High as FDA Approves Adult Lupus Nephritis Drug
Source: Streetwise Reports (01/25/2021)

Shares of Aurinia Pharmaceuticals traded 30% higher after the company reported that the U.S. Food and Drug Administration approved its LUPKYNIS™ (voclosporin) for use in treating adults with active lupus nephritis.

AzurRx Doses First Two People in Expanded Phase 2b Trial of Cystic Fibrosis Patients
Source: Streetwise Reports (01/22/2021)

AzurRx BioPharma shares traded 45% higher after the firm advised it had dosed the first two patients in its Phase 2b OPTION 2 Extension Study of MS1819 for treatment of exocrine pancreatic insufficiency in patients with cystic fibrosis.

NGL Energy Shares Rise 21% as It Seeks to Raise $2.05 Billion from Senior Secured Note Offering
Source: Streetwise Reports (01/21/2021)

Shares of NGL Energy Partners LP traded higher after the firm made a series of announcements over the past three days regarding an update on financial operations, a settlement with a customer in bankruptcy, a quarterly Class D unit distribution and a $2.05 billion senior secured debt offering.

Explorer Discovers New Gold Mineralization at Abitibi Gold Belt Property
Source: Streetwise Reports (01/21/2021)

iMetal Resources is setting out to see if the multi-million ounce gold resource next door continues onto its Gowganda West property in Ontario.

Gritstone Oncology Licenses LNP Platform from Genevant Sciences to Develop COVID-19 Vaccine
Source: Streetwise Reports (01/20/2021)

Shares of Gritstone Oncology reached a new 52-week high price after the company advised it entered into a non-exclusive licensing agreement with Genevant Sciences to develop and commercialize self-amplifying RNA vaccines for use against SARS-CoV-2.